Skip to content
HowShorted

AYTU BIOPHARMA, INC short interest in 2021

In 2021, AYTU BIOPHARMA, INC's disclosed short interest ran from 1.90% of shares outstanding on 12 Feb 2021 to 5.41% on 31 Dec 2021, a change of +3.51 percentage points. The year's high was 11.62% on 30 Apr 2021 and its low 1.90% on 12 Feb 2021, averaging 7.15% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.97 days on 29 Oct 2021. Full history: AYTU BIOPHARMA, INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for AYTU BIOPHARMA, INC in 2021

2021 in figures

Start of year
1.90% (12 Feb 2021)
End of year
5.41% (31 Dec 2021)
Change
+3.51 pp
High
11.62% (30 Apr 2021)
Low
1.90% (12 Feb 2021)
Average
7.15%
Highest days to cover
7.97 (29 Oct 2021)
SEC filings marked
8

Every report in 2021

AYTU BIOPHARMA, INC short interest in 2021
SettlementShort interestDays to coverFilings since previous
12 Feb 20211.90%1.0010-Q filed, results (8-K)
26 Feb 20212.08%1.00
15 Mar 20213.34%1.00
31 Mar 20218.29%1.26
15 Apr 202110.34%4.16
30 Apr 202111.62%7.41
14 May 20219.23%4.59
28 May 20219.90%6.6710-Q filed, results (8-K)
15 Jun 202110.18%1.75
30 Jun 20216.37%1.00
15 Jul 20217.76%3.16
30 Jul 20218.75%5.19
13 Aug 20217.98%5.58
31 Aug 20217.50%5.93
15 Sep 20218.12%5.45
30 Sep 20217.74%4.01results (8-K), 10-K filed
15 Oct 20215.33%7.74
29 Oct 20217.01%7.97
15 Nov 20215.76%4.4010-Q filed, results (8-K)
30 Nov 20216.25%3.04
15 Dec 20216.35%1.78
31 Dec 20215.41%2.70

See also: AYTU BIOPHARMA, INC's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.